CONRAY 43 430 MG — DIN 00477095
IOTHALAMATE MEGLUMINE : 430 MG · LIEBEL-FLARSHEIM CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is CONRAY 43?
CONRAY 43 430 MG contains IOTHALAMATE MEGLUMINE : 430 MG. It is listed in the Health Canada Drug Product Database under DIN 00477095, held by LIEBEL-FLARSHEIM CANADA INC, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as cancelled post market, status dated 07-May-2018. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CONRAY 43 used for?
Excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, cholangiography, ERCP, and contrast enhancement in CT and digital subtraction angiography.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Iotalamic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Iotalamic Acid, across 8 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TYCO HEALTHCARE | 3 | 0 | CONRAY 325, CONRAY 400, VASCORAY | No marketed DIN |
| LIEBEL-FLARSHEIM CANADA INC | 2 | 0 | CONRAY 30, CONRAY 43 | No marketed DIN |
| LIEBEL-FLARSHEIM COMPANY LLC | 2 | 0 | CONRAY 60, CYSTO-CONRAY II | No marketed DIN |
| MALLINCKRODT CANADA INC. | 1 | 0 | CYSTO CONRAY INJ 43% | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 430 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVASCULAR |
| Pack configuration (monograph) | Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section). |
| Storage | Not explicitly detailed in provided text (refers to Storage and Stability section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Iotalamic Acid |
|---|---|
| ATC code | V08AA04 |
| AHFS class | 36:68.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00477095 |
|---|---|
| DIN (unpadded, as printed on some documents) | 477095 |
| Brand name | CONRAY 43 |
| Generic / active ingredient | IOTHALAMATE MEGLUMINE : 430 MG |
| Market authorization holder | LIEBEL-FLARSHEIM CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | V08AA04 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AA |
| Current status | CANCELLED POST MARKET |
| Status date | 07-May-2018 |
| Original market date | 1980-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Intravenous infusion urography: Conray 30 (2-4 mL/kg, max 300 mL); Conray 43 (2-3 mL/kg, max 200 mL). Infusion rate approx. 40-50 mL/min. Dosage for children adjusted by age/weight.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug/container; anuria or severe oliguria. Not for myelography or subarachnoid communication. Contraindicated in certain acute biliary/pancreatic conditions and CT brain enhancement for suspected subarachnoid hemorrhage.
Warnings and precautions
Serious thromboembolic events (MI, stroke) possible. Risk of anuria/death in multiple myeloma patients. Extreme caution in pheochromocytoma and sickle cell disease. Risk of thyroid dysfunction.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CONRAY 30 | 300 MG | SOLUTION | LIEBEL-FLARSHEIM CANADA INC | CANCELLED POST MARKET | 00223107 |
| CONRAY 325 | 54.3 % | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | 00405302 |
| CONRAY 400 | 66.8 % | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | 00131547 |
| CONRAY 60 | 600 MG | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | 00131237 |
| CYSTO CONRAY INJ 43% | 430 MG | LIQUID | MALLINCKRODT CANADA INC. | CANCELLED POST MARKET | 00274194 |
| CYSTO-CONRAY II | 172 MG | SOLUTION | LIEBEL-FLARSHEIM COMPANY LLC | CANCELLED POST MARKET | 00397466 |
| VASCORAY | 260 MG | SOLUTION | TYCO HEALTHCARE | CANCELLED POST MARKET | 00131628 |
2 · Same class — other molecules in ATC V08AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diatrizoic Acid | GASTROGRAFIN · GASTROGRAFIN LIQ · HYPAQUE ORAL LIQUID - 50G/120ML · HYPAQUE ORAL LIQUID 50GM/120ML · +26 more | 30 | 1 | Yes |
| Iotalamic Acid | CONRAY 30 · CONRAY 325 · CONRAY 400 · CONRAY 43 · +4 more | 8 | 0 | Not in Canada |
| Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | SINOGRAFIN · SINOGRAFIN - LIQ IU | 2 | 0 | Not in Canada |
| Ioxitalamic Acid | TELEBRIX 38 ORAL | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AB | Iodixanol · Iohexol · Iopamidol · Iopromide · Iotrolan · +2 more | 45 | 14 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.